Publication & Citation Trends
Most Cited Works
Publications
18 total
<p>Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <em>ALK</em> Gene Have Durable Responses to ALK Kinase Inhibitors</p> PDF
Cited by 3
OpenAlex
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors PDF
Cited by 3
OpenAlex
Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 OA
Cited by 91
Semantic Scholar
Phase 2 study of <scp>RO</scp>4929097, a gamma‐secretase inhibitor, in metastatic melanoma: <scp>SWOG</scp> 0933 PDF
Cited by 90
OpenAlex
Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933.
Cited by 0
Semantic Scholar
A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
Cited by 67
OpenAlex
A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer PDF
Cited by 19
OpenAlex
Research Topics
Cancer Treatment and Pharmacology
(9)
Lung Cancer Treatments and Mutations
(7)
Colorectal Cancer Treatments and Studies
(5)
HER2/EGFR in Cancer Research
(3)
Lung Cancer Research Studies
(3)
Frequent Co-Authors
Affiliations
Mount Carmel Health
Georgetown University
Thomas Jefferson University Hospital
Holy Cross Hospital
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute